New Diabetes Drug Launched: Affordable Treatment Revolution in India
Alkem's commitment to global health improvement is reflected in its diverse product offerings and international presence.
Alkem Laboratories Limited has launched a new generic version of empagliflozin in India under the brand name "Empanorm." Empagliflozin is a Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitor used for treating type-2 diabetes mellitus, chronic kidney disease, and heart failure. Alkem's version is priced approximately 80 per cent lower than the innovator products, making it more accessible to patients. The company has incorporated an anti-counterfeit band and comprehensive patient education information on the packaging, including details in Hindi and English, with QR codes offering additional information in 11 languages. The tablets are designed to be smaller for patient convenience. Additionally, Alkem has introduced combinations of empagliflozin with other drugs under various brand names such as "Empanorm L," "Empanorm Duo," "Alsita E," and "Empanorm M." Dr. Vikas Gupta, CEO of Alkem, emphasized the importance of this launch in expanding their chronic portfolio and improving health outcomes across India.
DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, do download the service details here.
Company Overview
Alkem Laboratories Ltd. is a prominent Indian pharmaceutical company known for its high-quality medicines over the past 50 years. It ranks as the fifth-largest pharmaceutical company in India, with a strong presence in anti-infectives, gastrointestinal, and pain management drugs. The company is expanding its portfolio in chronic therapies, including diabetes, neurology, and cardiology. Alkem operates 19 manufacturing facilities and R&D centres in India and the US. The company's stock is currently priced at Rs 4,790, with a market capitalisation of over Rs 57,000 crore. Over the past three years, the stock has delivered a return of 41.16 per cent. Alkem's commitment to global health improvement is reflected in its diverse product offerings and international presence.
Disclaimer: The article is for informational purposes only and not investment advice.